Takashi et al[9] demonstrated that osimertinib regressed bone tumors in mice with EGFR-mutant lung adenocarcinoma and bone metastases, resulting in improved survival and bone remodeling in the mice. This evidence concerns the gene EGFR and bone neoplasm.